Determining the role of free fatty acids in developing e-cigarette-induced cardiac dysfunction
Project Number3U54MD007598-14S2
Former Number5U54MD007598-13
Contact PI/Project LeaderVADGAMA, JAYDUTT V.
Awardee OrganizationCHARLES R. DREW UNIVERSITY OF MED & SCI
Description
Abstract Text
Project Summary/Abstract:
Electronic cigarettes (e-cigarettes) are becoming exceptionally popular worldwide as an alternative to
conventional nicotine cigarettes, both in smokers and people who have never smoked. Adipose tissue can alter
the heart's function via the secretion of free fatty acids, adipokines, and bioactive molecules, thus making it a
critical endocrine regulator of whole-body metabolism. E-cigarettes can induce lipolysis in adipose tissue
producing the release of free fatty acids (FFAs). FSP27 is a lipid droplet-associated protein with anti-lipolytic
action. FFAs are a well-characterized factor for causing lipotoxicity and oxidative stress. Oxidative stress plays
a significant role in the inflammatory, metabolic and contractile changes of the dysfunctional heart. The CD36
receptor plays a role in enabling fatty acid transport to the heart. EP80317, a ligand to CD36, reduces myocardial
fatty acid uptake and is cardioprotective.
In our preliminary data, we examined the effects of an antihyperlipidemic drug, acipimox, that blocks lipolysis on
e-cigarettes induced cardiac dysfunction. To study the cardiac effect of e-cigarettes, we used C57BL/6 mice on
a high-fat diet, a commonly used murine model, to study cardiometabolic disease. Mice were exposed to saline,
e-cigarettes with nicotine (2.4%), or e-cigarette (2.4%) plus acipimox for 12 weeks. Fractional shortening and
ejection fraction was decreased in mice exposed to e-cig (2.4%), compared with saline and e-cig (2.4%) +
acipimox. Therefore, acipimox rescued the e-cigarette-induced cardiac dysfunction. Mice exposed to e-
cigarettes have increased circulating levels of M-CSF, IL-6, and FFAs, which were normalized by acipimox. HO-
1, an oxidative stress marker, was increased in the hearts of mice exposed to e-cigarettes compared to saline.
However, HO-1 levels in the e-cig (2.4%)+ acipimox group were normal. Moreover, apurinic/apyrimidinic (AP)
sites, a manifestation of DNA damage, were increased in the hearts of mice exposed to e-cig (2.4%) compared
to the saline group. AP sites levels of hearts from mice treated with acipimox were similar to the saline group.
Therefore, acipimox normalizes the e-cigarettes-induced cardiac dysfunction and normalizes the inflammatory
phenotype induced by e-cigarettes. In this study, our specific aims are: Aim 1 will evaluate whether adipocyte-
specific overexpression of FSP27 prevents e-cigarette-induced cardiac dysfunction. Aim 2 will determine
whether EP80317, a CD36-selective ligand that inhibits fatty acids uptake, confers a cardioprotective effect in
the e-cigarette-induced cardiac dysfunction model. Understanding the impact of elevated serum FFAs on e-
cigarettes-induced cardiac dysfunction will be crucial to curb the detrimental cardiac effects of e-cigarettes.
Public Health Relevance Statement
Project Narrative:
Despite the lack of information about possible cardiac effects, electronic cigarette use by youth has increased at
an alarming rate. In this project, I am proposing experiments to determine the effects of lipolysis and free fatty
acids cardiac uptake in electronic-cigarette-induced cardiac dysfunction. Our ultimate goal is the development
of effective medical therapies to prevent electronic-cigarette-induced cardiac dysfunction.
National Institute on Minority Health and Health Disparities
CFDA Code
307
DUNS Number
785877408
UEI
PFBDNBDS57H3
Project Start Date
28-September-2009
Project End Date
29-February-2024
Budget Start Date
01-March-2022
Budget End Date
28-February-2023
Project Funding Information for 2022
Total Funding
$71,750
Direct Costs
$50,000
Indirect Costs
$21,750
Year
Funding IC
FY Total Cost by IC
2022
National Institute on Drug Abuse
$71,750
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U54MD007598-14S2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U54MD007598-14S2
Patents
No Patents information available for 3U54MD007598-14S2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U54MD007598-14S2
Clinical Studies
No Clinical Studies information available for 3U54MD007598-14S2
News and More
Related News Releases
No news release information available for 3U54MD007598-14S2
History
No Historical information available for 3U54MD007598-14S2
Similar Projects
No Similar Projects information available for 3U54MD007598-14S2